SeaBioTech is an EU-FP7 project designed and driven by SMEs to create innovative marine biodiscovery pipelines as a means to convert the potential of marine biotechnology into novel industrial products for the pharmaceutical, cosmetic, aquaculture, functional food and industrial chemistry sectors. To achieve its goals, SeaBioTech brings together leading experts in biology, genomics, natural product chemistry, bioactivity testing, industrial bioprocessing, legal aspects, market analysis and knowledge-exchange.SeaBioTech targets novel marine endosymbiotic bacteria from unique and previously untapped habitats, including geothermal intertidal biotopes in Iceland, hydrothermal vent fields and deep sea oligotrophic basins of the Eastern Mediterranean Sea, and under-explored areas of Scottish coasts that are likely to be highly productive sources of new bioactive compounds. This chapter describes the four-years of activity in the SeaBioTech project, which resulted in a robust, validated workflow suitable for evaluating unexplored activities in marine samples to prioritise potential products for a biotechnological pipeline. An improved integrated methodology involving metagenomics and metabolomics were extensively utilised to prioritise five extremophiles as potential antibiotics, anti-cancer drugs and as novel drugs against metabolic diseases as well as new pharmaceutical excipients to the pipeline. A SeaBiotech | Edrada-Ebel et al.